Start Investing in StocksTraders beat market returns with our 4X Leverage on Equity Delivery.
Home/ Stocks/ LASA


₹26 2.008.33 %(in 1 day)

LASA Fundamentals

Dividend Yield
P/E Ratio
P/B Ratio
Debt to Equity

LASA Financials

26.66 CrDec'23 (Standalone)
All values in Rs. Cr
Shareholding Pattern
About Company

Lasa Supergenerics Limited was incorporated on March 11, 2016. The Company is primarily engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc. The Company is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain-from discovery-to-delivery, with established credentials in research, manufacturing and global marketing. The Company is a veterinary API manufacturing entity, which was acquired in April, 2012. The manufacturing facility is located at Mahad & Chiplun, in the Konkan region of Maharashtra. It specialises in catalyst chemistry and manufactures anthelmintic / veterinary API products with largest production capabilities and product categories in India. To efficiently control the supply chain, the Company is fully backward integrated for its key molecules-from discovery research up to full-scale bulk production. The Companys marketing footprint is entrenched across developing markets in multiple countries. Similarly, the group expects to augment its export footprint significantly in width and depth in the future.The Company announced the launching of 2 new block buster products with all-time strong segment, Oxycozanide. Oxyclozanide is an anthelmintic, used in the treatment and control of fascioliasis a topical worm infection in ruminants mainly domestic animals such as cattle, especially buffalos in farm, sheep, and goats. For this, the Company is setting up capacity in a brown field expansion at its Chiplun unit with a total capacity of 20 MT. It has got huge demand all over the globe as it is manufactured and have strong entry barriers. Likewise, this product fits in product selection criteria, through which the Company is confident of grabbing significant market share.Due to floods and fire in the company units, the launch of another block buster product was deferred and commercialization of Oxyclozanide prolonged for some time to accommodate existing products in the company. The company received WHO Certificate of Good Manufacturing Practices from the Food and Drug Administration authorities for its manufacturing facility situated at Khed, Ratnagiri.The Company has alliances with leading Indian and global animal health care conglomerates and uses Good Manufacturing Practice (GMP) and world-class technologies in its operations. The Company is managed by a consortium of technocrats, including its Chairman and Managing Director Mr. Omkar P. Herlekar who are impelled by passion and propelled by niche innovation. The leadership team, which is guided by these values, is well positioned to lead into the future.The Company is determined to achieve of becoming a leading force in the niche animal health care solutions. The objective on which it was founded have always inspired sustainable growth through innovation and shall continue to do so. Today, the Company is the leading manufacturer player in veterinary APIs in India, with a well-established brand known for its high-quality products amongst various customers.
Show More
Similar stocks

Ans: Share price of LASA SUPERGENERICS LTD is 26 today.

Ans: LASA SUPERGENERICS LTD opened at 26 today.

Ans: LASA SUPERGENERICS LTD closed at 24 previous trading day

Ans: Today's High price of LASA SUPERGENERICS LTD is : 26 and Today's Low price of LASA SUPERGENERICS LTD is : 25

Ans: 52 weeks High price of LASA SUPERGENERICS LTD is : 35

Ans: 52 weeks High price of LASA SUPERGENERICS LTD is : 22

Ans: P/E ratio of LASA SUPERGENERICS LTD is : 0

Ans: P/B ratio of LASA SUPERGENERICS LTD is : 0.78

Ans: You can buy/sell LASA SUPERGENERICS LTD through Rupeezy App or Rupeezy Web